Sort   by:  
 Page size 
UnknownPhase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Not available
S-EPMC3782148 | biostudies-literature
UnknownCabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Not available
S-EPMC4383838 | biostudies-literature
UnknownTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Not available
S-EPMC4872347 | biostudies-literature
UnknownUpdated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Not available
S-EPMC4418928 | biostudies-literature
UnknownTumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
Not available
S-EPMC7472556 | biostudies-literature
UnknownMarital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.
Not available
S-EPMC10922505 | biostudies-literature
UnknownManagement of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Not available
S-EPMC7614721 | biostudies-literature
UnknownWhat Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Not available
S-EPMC8849852 | biostudies-literature
Sort   by:  
 Page size